Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Innovation/Tech Officer

SVP, Operations

SVP, Research & Development

President and CEO

See Remark

SVP, General Counsel

SVP, Chief Financial Officer

Chief Medical Officer

SVP, Chief Commercial Officer

SVP-Bus. Process & Info. Tech.

General Counsel

Chief Executive Officer

CEO and President

SVP-Chief Financial Officer

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to addres...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-15	Premium	sold	Premium	Premium	Premium	Chief Innovation/Tech Officer
2024-03-10	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Operations
2024-03-10	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Research & Development
2024-03-09	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2024-03-09	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Research & Development
2024-03-09	Premium	sold (taxes)	Premium	Premium	Premium	See Remark
2024-03-09	Premium	sold (taxes)	Premium	Premium	Premium	SVP, General Counsel
2024-03-09	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Operations
2024-03-09	Premium	sold (taxes)	Premium	Premium	Premium	Chief Innovation/Tech Officer
2024-03-09	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-03-08	Premium	sold	Premium	Premium	Premium	Chief Innovation/Tech Officer
2024-03-07	Premium	acquired	Premium	Premium	Premium	SVP, Operations
2024-03-07	Premium	acquired	Premium	Premium	Premium	SVP, General Counsel
2024-03-07	Premium	acquired	Premium	Premium	Premium	Chief Innovation/Tech Officer
2024-03-07	Premium	acquired	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-03-07	Premium	acquired	Premium	Premium	Premium	See Remark
2024-03-07	Premium	acquired	Premium	Premium	Premium	SVP, Research & Development
2024-03-07	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-03-07	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-08-09	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-03-10	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Research & Development
2023-03-10	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Operations
2023-03-09	Premium	acquired	Premium	Premium	Premium	SVP, Operations
2023-03-09	Premium	acquired	Premium	Premium	Premium	See Remark
2023-03-09	Premium	acquired	Premium	Premium	Premium	SVP, Research & Development

AQST - Aquestive Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for AQST